Cited by 194Down syndrome and intellectual disability researchGenetics and Neurodevelopmental DisordersWilliams Syndrome Research

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome

Open access

Dowjat, Wieslaw K., Adayev, Tatyana, Kuchna, Izabela, Nowicki, Krzysztof, Palminiello, Sonia, Hwang, Yu Wen, Wegiel, Jerzy·2007·Neuroscience Letters

DOI 10.1016/j.neulet.2006.11.026PMC PMC1890010

Open this paper in CoChat — free account

Abstract

Down syndrome (DS) is the most common genetic disorder associated with mental retardation (MR). It is believed that many of the phenotypic features of DS stem from enhanced expression of a set of genes located within the triplicated region on chromosome 21. Among those genes is DYRK1A encoding dual-specificity proline-directed serine/treonine kinase, which, as documented by animal studies, can potentially contribute to cognitive deficits in DS. Whether this contribution can be exerted through elevated levels of DYRK1A protein in the brain of DS subjects was the main goal of the present study. The levels of DYRK1A protein were measured by Western blotting in six brain structures that included cerebral and cerebellar cortices and white matter. The study involved large cohorts of DS subjects and age-matched controls representing infants and adults of different age, gender and ethnicity. Trisomic Ts65Dn mice, an animal model of DS, were also included in the study. Both in trisomic mice and in DS subjects, the brain levels of DYRK1A protein were increased approximately 1.5-fold, indicating that this protein is overexpressed in gene dosage-dependent manner. The exception was an infant group, in which there was no enhancement suggesting the existence of a developmentally regulated mechanism. We found DYRK1A to be present in every analyzed structure irrespective of age. This widespread occurrence and constitutive expression of DYRK1A in adult brain suggest an important, but diverse from developmental role played by this kinase in adult central nervous system. It also implies that overexpression of DYRK1A in DS may be potentially relevant to MR status of these individuals during their entire life span.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neulet.2006.11.026

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Down syndrome phenotypes: the consequences of chromosomal imbalance.
Korenberg, J. R., Chen, X. N., Schipper, R. D., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N. J., Däumer, C., Dignan, P. S. J., & Distèche, C. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4997 · Cited by 784
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome
Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 408
Untitled work
(1990) · PubMed · Cited by 351
Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice
Fotaki, V., Dierssen, M., Alcántara, S., Martínez, S., Martí, E., Casas, C., Visa, J., Soriano, E., Estivill, X., & Arbonés, M. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6636-6647.2002 · Cited by 344
A Chromosome 21 Critical Region Does Not Cause Specific Down Syndrome Phenotypes
Olson, L. E., Richtsmeier, J. T., Leszl, J. M., & Reeves, R. H. (2004) · Science · doi:10.1126/science.1098992 · Cited by 331
The Consequences of Chromosome Imbalance
Epstein, C. J. (1986) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529702 · Cited by 309
down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis.
Wisniewski, K. E. (2005) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320370755 · Cited by 297
Down's syndrome: a genetic disorder in biobehavioral perspective
Nadel, L. (2003) · Genes Brain & Behavior · doi:10.1034/j.1601-183x.2003.00026.x · Cited by 291
Dendritic atrophy in children with down’s syndrome.
Becker, L. E., Armstrong, D. L., & Chan, F. (1986) · Annals of Neurology · doi:10.1002/ana.410200413 · Cited by 279
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects
Ahn, K.-J., Jeong, H. K., Choi, H.-S., Ryoo, S.-R., Kim, Y. J., Goo, J.-S., Choi, S.-Y., Han, J.-S., Ha, I., & Song, W.-J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.006 · Cited by 220

Flagged first, then by citations

Show all 32 references

2 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 683
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
The dendritic tree and brain disorders
Kulkarni, V. A., & Firestein, B. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.03.005 · Cited by 390
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
The role of DYRK1A in neurodegenerative diseases
Węgiel, J., Gong, C., & Hwang, Y. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 307
Self-citation
Genome-wide association scan for five major dimensions of personality
Terracciano, A., Sanna, S., Uda, M., Deiana, B., Usala, G., Busonero, F., Maschio, A., Scally, M., Patriciu, N. S., Chen, W.-M., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.113 · Cited by 295
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuyà, H., et al. (2010) · Nature Communications · doi:10.1038/ncomms1090 · Cited by 276
Ohnologs in the human genome are dosage balanced and frequently associated with disease
Makino, T., & McLysaght, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914697107 · Cited by 284
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome
Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272
Self-citation
Down syndrome--recent progress and future prospects
Wiseman, F. K., Alford, K. A., Tybulewicz, V. L. J., & Fisher, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp010 · Cited by 259
Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease
Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 238
Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
Guedj, F., Sebrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E. M., Gillet, B., Arbonés, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004606 · Cited by 227
MNB/DYRK1A as a multiple regulator of neuronal development
Tejedor, F. J., & Hämmerle, B. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07954.x · Cited by 214
Function and regulation of Dyrk1A: towards understanding Down syndrome
Park, J., Song, W., & Chung, K. C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0123-2 · Cited by 212
Rodent models in Down syndrome research: impact and future opportunities
Hérault, Y., Delabar, J. M., Fisher, E., Tybulewicz, V. L. J., Yu, E. Y., & Brault, V. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029728 · Cited by 206
Trisomy 21 and early brain development
Haydar, T. F., & Reeves, R. H. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.001 · Cited by 200
The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation
Soppa, U., Schumacher, J., Florencio Ortiz, V., Pasqualon, T., Tejedor, F., & Becker, W. (2014) · Cell Cycle · doi:10.4161/cc.29104 · Cited by 189
“5-fold overexpressed in Down syndrome.(17,18) Evidence from transgenic mouse models as well as studies in chicken and Drosophila (where the DYRK1A orthologs are termed Minibrain) have revealed that both overexpression and reduced expression of DYRK1A result in neurodevelopmental alterations due to deregulation of neur…”
Background
DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome
Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181
DYRK1A and cognition: A lifelong relationship
Arbonés, M. L., Thomazeau, A., Nakano-Kobayashi, A., Hagiwara, M., & Delabar, J. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.010 · Cited by 174
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly
Møller, R. S., Kübart, S., Hoeltzenbein, M., Heye, B., Vogel, I., Hansen, C. P., Menzel, C., Ullmann, R., Tommerup, N., Ropers, H.-H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.03.001 · Cited by 163
DYRK1A: A master regulatory protein controlling brain growth
Guedj, F., Pereira, P. L., Najas, S., Barallobre, M. J., Chabert, C., Souchet, B., Sebrié, C., Verney, C., Hérault, Y., Arbonés, M. L., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.007 · Cited by 168
Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets
Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 171
Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition
Soundararajan, M., Roos, A. K., Savitsky, P. A., Filippakopoulos, P., Kettenbach, A. N., Olsen, J. V., Gerber, S. A., Eswaran, J., Knapp, S., & Elkins, J. M. (2013) · Structure · doi:10.1016/j.str.2013.03.012 · Cited by 160
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy
Conti, A. M. F., Fabbrini, F., D'Agostino, P., Negri, R., Greco, D., Genesio, R., D'Armiento, M. R., Olla, C., Paladini, D., Zannini, M., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-268 · Cited by 143
Untitled work
(2012) · PubMed
Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells
Park, J., Oh, Y., Yoo, L., Jung, M.-S., Song, W.-J., Lee, S.-H., Seo, H., & Chung, K. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147520 · Cited by 134
Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)
Adayev, T., Węgiel, J., & Hwang, Y. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.024 · Cited by 124
Self-citation
Minibrain/Dyrk1a Regulates Food Intake through the Sir2-FOXO-sNPF/NPY Pathway in Drosophila and Mammals
Hong, S.-H., Lee, K., Kwak, S., Kim, A., Bai, H., Jung, M., Kwon, O., Song, W., Tatar, M., & Yu, K. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002857 · Cited by 123
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy
Courcet, J.-B., Faivre, L., Malzac, P., Masurel-Paulet, A., Lopez, E., Callier, P., Lambert, L., Lemesle, M., Thevenon, J., Gigot, N., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101251 · Cited by 121
Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage
Souchet, B., Guedj, F., Sahún, I., Duchon, A., Daubigney, F., Badel, A., Yanagawa, Y., Barallobre, M. J., Dierssen, M., Yu, E. Y., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.016 · Cited by 117
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome
Węgiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur‐Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, ‌., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0419-6 · Cited by 113
Self-citation
Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome
Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98
Self-citation
Selective inhibition of the kinase DYRK1A by targeting its folding process
Kii, I., Sumida, Y., Goto, T., Sonamoto, R., Okuno, Y., Yoshida, S., Kato‐Sumida, T., Koike, Y., Abe, M., Nonaka, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11391 · Cited by 94
mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
Di Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89
Aberrant phosphorylation in the pathogenesis of Alzheimer's disease
Chung, S. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.467 · Cited by 92
Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1
Park, J., Oh, Y., & Chung, K. C. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.1.006 · Cited by 86
Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A
Fernandez-Martinez, J., Vela, E. M., Tora-Ponsioen, M., Ocaña, O. H., Nieto, M., & Galceran, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.044354 · Cited by 81
The spatio‐temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development
Hämmerle, B., Elizalde, C., & Tejedor, F. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06092.x · Cited by 82
The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4
Sitz, J. H., Baumgärtel, K., Hämmerle, B., Papadopoulos, C., Hekerman, P., Tejedor, F. J., Becker, W. B., & Lutz, B. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.034 · Cited by 79
The DREAM complex functions as conserved master regulator of somatic DNA-repair capacities
Bujarrabal-Dueso, A., Sendtner, G., Meyer, D. H., Chatzinikolaou, G., Stratigi, K., Garinis, G. A., & Schumacher, B. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-00942-8 · Cited by 79
Activity-dependent facilitation of Synaptojanin and synaptic vesicle recycling by the Minibrain kinase
Chen, C., Brégère, C., Paluch, J., Lu, J. F., Dickman, D. K., & Chang, K. T. (2014) · Nature Communications · doi:10.1038/ncomms5246 · Cited by 77
Down syndrome and the enteric nervous system
Moore, S. W. (2008) · Pediatric Surgery International · doi:10.1007/s00383-008-2188-7 · Cited by 79
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 71
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of down syndrome
Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75
Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models
Souchet, B., Guedj, F., Penke-Verdier, Z., Daubigney, F., Duchon, A., Hérault, Y., Bizot, J., Janel, N., Créau, N., Delatour, B., et al. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00267 · Cited by 77
Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity
Gourdain, S., Dairou, J., Denhez, C., Bui, L. C., Rodrigues‐Lima, F., Janel, N., Delabar, J. M., Cariou, K., & Dodd, R. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401049v · Cited by 79
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)
Mott, B. T., Tanega, C., Shen, M., Maloney, D. J., Shinn, P., Leister, W., Marugán, J., Inglese, J., Austin, C. P., Misteli, T., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.121 · Cited by 77
The WD40‐repeat protein Han11 functions as a scaffold protein to control HIPK2 and MEKK1 kinase functions
Ritterhoff, S., Farah, C. M., Grabitzki, J., Lochnit, G., Skurat, A. V., & Schmitz, M. L. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.251 · Cited by 71
DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome
Ortiz-Abalia, J., Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., & Fillat, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.09.010 · Cited by 70
Using mouse models to explore genotype–phenotype relationship in Down syndrome
Salehi, A., Faizi, M., Belichenko, P. V., & Mobley, W. C. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20164 · Cited by 70
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair
Guard, S. E., Poss, Z. C., Ebmeier, C. C., Pagratis, M., Simpson, H., Taatjes, D. J., & Old, W. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42990-5 · Cited by 72
GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome
Martín, J. Z. D. S., Delabar, J. M., Bacci, A., & Potier, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.002 · Cited by 70
Trisomy 21 and Down syndrome: a short review
Sommer, C., & Henrique‐Silva, F. (2008) · Brazilian Journal of Biology · doi:10.1590/s1519-69842008000200031 · Cited by 59
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes
Stringer, M., Abeysekera, I., Thomas, J. R., LaCombe, J., Stancombe, K., Stewart, R. B., Dria, K. J., Wallace, J. M., Goodlett, C. R., & Roper, R. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.05.003 · Cited by 64
Altered regulation of tau phosphorylation in a mouse model of down syndrome aging
Sheppard, O., Plattner, F., Rubin, A. N., Slender, A., Linehan, J. M., Brandner, S., Tybulewicz, V. L. J., Fisher, E., & Wiseman, F. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.025 · Cited by 55
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6
Yamamoto, T., Shimojima, K. Y., Nishizawa, T., Matsuo, M., Ito, M., & Imai, K. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33735 · Cited by 56
DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase
Noll, C., Planque, C., Ripoll, C., Guedj, F., Díez-Betriu, A., Ducros, V., Belin, N., Duchon, A., Paul, J., Badel, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007540 · Cited by 54
Therapeutic approaches in the improvement of cognitive performance in Down syndrome
de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53
Promotion of Neuronal Plasticity by (−)-Epigallocatechin-3-Gallate
Xie, W. Q., Ramakrishna, N., Wieraszko, A., & Hwang, Y. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9494-7 · Cited by 53
Self-citation
DYRK1A-mediated phosphorylation of GluN2A at Ser1048 regulates the surface expression and channel activity of GluN1/GluN2A receptors
Grau, C. J. A., Arató, K., Fernández‐Fernández, J. M., Valderrama, A., Sindreu, C. B., Fillat, C., Ferrer, I., de la Luna, S., & Altafaj, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00331 · Cited by 46
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits
Stringer, M., Goodlett, C. R., & Roper, R. J. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.334 · Cited by 45
Down syndrome, beta-amyloid and neuroimaging
Head, E., Helman, A. M., Powell, D. K., & Schmitt, F. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.013 · Cited by 49
Dyrk1A Binds to Multiple Endocytic Proteins Required for Formation of Clathrin-Coated Vesicles
Murakami, N., Bolton, D., & Hwang, Y. (2009) · Biochemistry · doi:10.1021/bi9010557 · Cited by 45
Self-citation
Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model
Stringer, M., Abeysekera, I., Dria, K. J., Roper, R. J., & Goodlett, C. R. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.002 · Cited by 42
Polyphenols in the management of brain disorders: Modulation of the microbiota-gut-brain axis
Serra, D., Almeida, L. M., & Dinis, T. C. P. (2019) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2019.08.001 · Cited by 46
Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases
Yang, Y., Fan, X., Liu, Y., Ye, D., Liu, C., Yang, H., Su, Z., Zhang, Y., & Liu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115521 · Cited by 43
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult down syndrome mice
Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43
Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance
Yang, Y., Xie, Y., Xu, Q., Chen, J. X., Shan, N. C., & Zhang, Y. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.015 · Cited by 42
Molecular mechanisms that mediate dendrite morphogenesis
Lefebvre, J. L. (2021) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2020.12.008 · Cited by 42
REST Regulates DYRK1A Transcription in a Negative Feedback Loop
Lü, M., Zheng, L., Han, B., Wang, L., Wang, P., Liu, H., & Sun, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174540 · Cited by 39
Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice
Mazur‐Kolecka, B., Golabek, A. A., Kida, E., Rabe, A., Hwang, Y., Adayev, T., Węgiel, J., Flory, M. J., Kaczmarski, W., Marchi, E. J., et al. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23007 · Cited by 44
Self-citation
Oxidative stress, thyroid dysfunction & Down syndrome
Casado, Á., & Campos, C. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.164218 · Cited by 38
Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome
Altafaj, X., Ortiz-Abalia, J., Fernández, M., Potier, M., Laffaire, J., Andreu, N., Dierssen, M., González-García, C., Ceña, V., Martı́, E., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.024 · Cited by 38
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation
Lee, S. B., Ko, A., Oh, Y. T., Shi, P., D’Angelo, F., Frangaj, B., Koller, A. A., Chen, E. I., Cardozo, T. J., Iavarone, A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.021 · Cited by 38
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives
Stagni, F., & Bartesaghi, R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903729 · Cited by 33
Phosphorylation by Dyrk1A of Clathrin Coated Vesicle-Associated Proteins: Identification of the Substrate Proteins and the Effects of Phosphorylation
Murakami, N., Bolton, D. C., Kida, E., Xie, W. Q., & Hwang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034845 · Cited by 37
Self-citation
Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1
Maenz, B., Hekerman, P., Vela, E. M., Galcerán, J., & Becker, W. B. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-30 · Cited by 37
Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome
Campos, C., Guzmán, R., López-Fernández, E., & Casado, Á. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.03.013 · Cited by 37
Copper homeostasis and the ubiquitin proteasome system
Zhang, B., & Burke, R. (2023) · Metallomics · doi:10.1093/mtomcs/mfad010 · Cited by 36
Developmental deficits and staging of dynamics of age associated Alzheimer’s disease neurodegeneration and neuronal loss in subjects with Down syndrome
Węgiel, J., Flory, M. J., Kuchna, I., Nowicki, K., Wegiel, J., Ma, S. Y., Zhong, N., Wierzba‐Bobrowicz, T., de Leon, M., Lai, F., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01300-9 · Cited by 35
Self-citation
Down syndrome is an oxidative phosphorylation disorder
Bayona‐Bafaluy, M. P., Garrido-Pérez, N., Meade, P., Iglesias, E., Jiménez-Salvador, I., Montoya, J., Martínez‐Cué, C., & Ruiz‐Pesini, E. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101871 · Cited by 33
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
Ashford, A. L., Dunkley, T. P. J., Cockerill, M. J., Rowlinson, R. A., Baak, L., Gallo, R., Balmanno, K., Goodwin, L., Ward, R. A., Lochhead, P. A., et al. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2032-x · Cited by 32
New Perspectives for the Rescue of Cognitive Disability in Down Syndrome
Bartesaghi, R., Haydar, T. F., Delabar, J. M., Dierssen, M., Martínez‐Cué, C., & Bianchi, D. W. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2775-15.2015 · Cited by 32
Disruption of neurogenesis and cortical development in transgenic mice misexpressing Olig2, a gene in the Down syndrome critical region
Liu, W. C., Zhou, H., Liu, L., Zhao, C., Deng, Y., Chen, L., Wu, L.-M. N., Mandrycky, N., McNabb, C. T., Peng, Y.-B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.021 · Cited by 31
Phosphorylation of Synaptojanin Differentially Regulates Endocytosis of Functionally Distinct Synaptic Vesicle Pools
Geng, J., Wang, L., Lee, J. Y., Chen, C., & Chang, K. T. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1470-16.2016 · Cited by 30
Structural analysis of pathogenic mutations in theDYRK1Agene in patients with developmental disorders
Evers, J. M. G., Laskowski, R. A., Bértoli, M., Clayton‐Smith, J., Deshpande, C., Eason, J., Elmslie, F., Flinter, F. A., Gardiner, C. A., Hurst, J. A., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw409 · Cited by 33
Dementia in people with intellectual disability: Insights and challenges in epidemiological research with an at-risk population
Evans, E. J., Bhardwaj, A. K., Brodaty, H., Sachdev, P. S., Draper, B., & Trollor, J. N. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.866938 · Cited by 28
Intracellular distribution of differentially phosphorylated dual‐specificity tyrosine phosphorylation‐regulated kinase 1A (DYRK1A)
Kaczmarski, W., Barua, M., Mazur‐Kolecka, B., Frackowiak, J., Dowjat, W. K., Mehta, P. D., Bolton, D., Hwang, Y., Rabe, A., Albertini, G., et al. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23279 · Cited by 28
Self-citation
Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions
Murphy, A. J., Wilton, S. D., Aung-Htut, M. T., & McIntosh, C. S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1391564 · Cited by 28
Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues
London, J., Rouch, C., Bui, L. C., Assayag, E., Souchet, B., Daubigney, F., Medjaoui, H., Luquet, S. H., Magnan, C., Delabar, J. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0591-6 · Cited by 29
HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase
Kadri, F., Pacifici, M., Wilk, A. M., Struckhoff, A. P., Valle, L. D., Hauser, K. F., Knapp, P. E., Parsons, C. H., Jeansonne, D. P., Lassak, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675751 · Cited by 26
Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay
Wang, D., Wang, F., Tan, Y., Dong, L., Chen, L., Zhu, W., & Wang, H. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.043 · Cited by 25
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase
Bui, L. C., Tabouy, L., Busi, F., Dupret, J., Janel, N., Planque, C., Delabar, J. M., Rodrigues‐Lima, F., & Dairou, J. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.12.024 · Cited by 24
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice
Arqué, G., de Lagrán, M. M., Arbonés, M. L., & Dierssen, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.027 · Cited by 26
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
Pucelik, B., Barzowska, A., Dąbrowski, J. M., & Czarna, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169083 · Cited by 23

Authors: Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J.
Affiliations: IRCCS San Raffaele Roma (IT)
Corresponding author: Dowjat, Wieslaw K.
ORCID: Dowjat, Wieslaw K.
Nowicki, Krzysztof
Venue: Neuroscience Letters
Publisher: Elsevier BV
Published: 2007-02
Volume: 413
Issue: 1
Pages: 77-81
ISSN: 0304-3940 (ISSN-L)
DOI: 10.1016/j.neulet.2006.11.026
PMC: PMC1890010
OpenAlex: W1964178482
Cited by: 190
References: 32
Citations by year: 2026: 4 · 2025: 5 · 2024: 5 · 2023: 14 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 9 · 2017: 14 · 2016: 9 · 2015: 12 · 2014: 11 · 2013: 8 · 2012: 17
FWCI: 9.36
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neuroscience Letters (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD043960, R01 HD43960, R01HD38295, R01HD038295)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
Keywords: Down syndrome, DYRK1A, gene dosage, protein overexpression, brain, intellectual disability, Ts65Dn mouse model, developmental regulation, adult central nervous system
MeSH terms: Dyrk Kinases, Adolescent, Adult, Age Factors, Aged, Animals, Child, Child, Preschool, Chromosomes, Human, Pair 21, Down Syndrome, Humans, Infant, Mice, Transgenic, Middle Aged, Protein-Tyrosine Kinases, Trisomy, Case-Control Studies, Protein Serine-Threonine Kinases, Gene Expression Regulation, Developmental, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks